PDF herunterladen
Pharmacopsychiatry
DOI: 10.1055/a-2550-6470
Review

Therapeutic Potential of the Novel GLP-1 Receptor Agonist Semaglutide in Alcohol Use Disorder

Tingting Liu   *
1   School of Chemical Engineering, Changchun University of Technology, Changchun, China
,
Fuqiang Shi   *
1   School of Chemical Engineering, Changchun University of Technology, Changchun, China
,
Zhihua Guo
1   School of Chemical Engineering, Changchun University of Technology, Changchun, China
,
Hongwu Li
1   School of Chemical Engineering, Changchun University of Technology, Changchun, China
,
Di Qin
2   The Third Bethune Hospital of Jilin University, Changchun, China
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
    Lizenzen und Reprints

Abstract

Alcohol use disorder (AUD) is a prevalent neuropsychiatric disorder with serious health and social consequences. However, few licensed and successful pharmacotherapies exist for heterogeneous and complex disorders such as AUD, and these are poorly utilized. Preclinical and clinical findings suggest that the glucagon-like peptide-1 (GLP-1) system, a gut-brain peptide, is involved in the neurobiology of addictive behaviors. Additionally, the GLP-1 receptor (GLP-1R) has become a promising target for the treatment of AUD. Semaglutide, a novel GLP-1R agonist, has received clinical approval to treat type 2 diabetes in both subcutaneous and oral dosage forms. Studies have shown that it significantly reduces alcohol consumption and relapse of alcohol addiction in rats, suggesting its potential effectiveness for treating alcohol abuse in humans, particularly in overweight patients with AUDs. However, the use of semaglutide is associated with potential risks, such as gallbladder disease and clinical complications associated with delayed gastric emptying. This review evaluates the safety of semaglutide to inform its wider clinical application. Further extensive and in-depth studies on semaglutide are needed to reveal additional valuable clinical benefits.

Keywords

alcohol use disorder - GLP-1 - GLP-1RA - semaglutide - semaglutide safety

* Tingting Liu and Fuqiang Shi contributed equally to this work and they both join first authorship.




Publikationsverlauf

Eingereicht: 05. Januar 2025

Angenommen: 24. Februar 2025

Artikel online veröffentlicht:
14. April 2025

© 2025. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Degenhardt L, Charlson F, Ferrari A. et al. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Psychiatry 2018; 5: 987-1012
    CrossrefPubMedSuche in Google Scholar
  • 2 World Health Organization. Global status report on alcohol and health 2018. Geneva: World Health Organization; 2018
    Suche in Google Scholar
  • 3 Grant BF, Goldstein RB, Saha TD. et al. Epidemiology of DSM-5 alcohol use disorder: Results from the National Epidemiologic Survey on Alcohol and Related Conditions III. JAMA Psychiatry 2015; 72: 757-766
    CrossrefPubMedSuche in Google Scholar
  • 4 Klausen MK, Thomsen M, Wortwein G. et al. The role of glucagon-like peptide 1 (GLP-1) in addictive disorders. Br J Pharmacol 2022; 179: 625-641
    CrossrefPubMedSuche in Google Scholar
  • 5 American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. 2013
    PubMedSuche in Google Scholar
  • 6 Koob GF, Volkow ND. Neurobiology of addiction: A neurocircuitry analysis. Lancet Psychiatry 2016; 3: 760-773
    CrossrefPubMedSuche in Google Scholar
  • 7 Carvalho AF, Heilig M, Perez A. et al. Alcohol use disorders. Lancet Lond Engl 2019; 394: 781-792
    CrossrefPubMedSuche in Google Scholar
  • 8 Jerlhag E. GLP-1 signaling and alcohol-mediated behaviors; preclinical and clinical evidence. Neuropharmacology 2018; 136: 343-349
    CrossrefPubMedSuche in Google Scholar
  • 9 Nauck MA, Quast DR, Wefers J. et al. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Mol Metab 2021; 46: 101102
    CrossrefPubMedSuche in Google Scholar
  • 10 Wilding JPH, Batterham RL, Calanna S. et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021; 384: 989-1002
    CrossrefPubMedSuche in Google Scholar
  • 11 Bucheit JD, Pamulapati LG, Carter N. et al. Oral semaglutide: A review of the first oral glucagon-like peptide 1 receptor agonist. Diabetes Technol Ther 2020; 22: 10-18
    CrossrefPubMedSuche in Google Scholar
  • 12 Chuong V, Farokhnia M, Khom S. et al. The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission. JCI Insight 2023; 8: e170671
    CrossrefPubMedSuche in Google Scholar
  • 13 Aranäs C, Edvardsson CE, Shevchouk OT. et al. Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats. EBioMedicine 2023; 93: 104642
    CrossrefPubMedSuche in Google Scholar
  • 14 Taşçı SK, Bingöl SA. GLP-1 Localisation and proglucagon gene expression in healthy and diabetic mouse ileum. J Vet Res 2018; 62: 237-242
    CrossrefPubMedSuche in Google Scholar
  • 15 Merchenthaler I, Lane M, Shughrue P. Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol 1999; 403: 261-280
    CrossrefPubMedSuche in Google Scholar
  • 16 Alhadeff AL, Rupprecht LE, Hayes MR. GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake. Endocrinology 2012; 153: 647-658
    CrossrefPubMedSuche in Google Scholar
  • 17 Cornu M, Yang J-Y, Jaccard E. et al. Glucagon-like peptide-1 protects β-cells against apoptosis by increasing the activity of an Igf-2/Igf-1 receptor autocrine loop. Diabetes 2009; 58: 1816-1825
    CrossrefPubMedSuche in Google Scholar
  • 18 Zummo FP, Cullen KS, Honkanen-Scott M. et al. Glucagon-like peptide 1 protects pancreatic β-cells from death by increasing autophagic flux and restoring lysosomal function. Diabetes 2017; 66: 1272-1285
    CrossrefPubMedSuche in Google Scholar
  • 19 Krieger J-P, Langhans W, Lee SJ. Vagal mediation of GLP-1’s effects on food intake and glycemia. Physiol Behav 2015; 152: 372-380
    CrossrefPubMedSuche in Google Scholar
  • 20 Abegg K, Schiesser M, Lutz TA. et al. Acute peripheral GLP-1 receptor agonism or antagonism does not alter energy expenditure in rats after Roux-en-Y gastric bypass. Physiol Behav 2013; 121: 70-78
    CrossrefPubMedSuche in Google Scholar
  • 21 Guerrero-Hreins E, Goldstone AP, Brown RM. et al. The therapeutic potential of GLP-1 analogues for stress-related eating and role of GLP-1 in stress, emotion and mood: A review. Prog Neuropsychopharmacol Biol Psychiatry 2021; 110: 110303
    CrossrefPubMedSuche in Google Scholar
  • 22 Hu D, Ch M, Ra P. Type 2 diabetes--therapy with dipeptidyl peptidase IV inhibitors. Biochim Biophys Acta 2005; 1751
    CrossrefPubMedSuche in Google Scholar
  • 23 Jerlhag E. The therapeutic potential of glucagon-like peptide-1 for persons with addictions based on findings from preclinical and clinical studies. Front Pharmacol 2023; 14: 1063033
    CrossrefPubMedSuche in Google Scholar
  • 24 Kolterman OG, Kim DD, Shen L. et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005; 62: 173-181
    CrossrefPubMedSuche in Google Scholar
  • 25 Knudsen LB, Nielsen PF, Huusfeldt PO. et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000; 43: 1664-1669
    CrossrefPubMedSuche in Google Scholar
  • 26 Aroda VR, DeYoung MB. Clinical implications of exenatide as a twice-daily or once-weekly therapy for type 2 diabetes. Postgrad Med 2011;
    CrossrefPubMedSuche in Google Scholar
  • 27 Finan B, Clemmensen C, Müller TD. Emerging opportunities for the treatment of metabolic diseases: Glucagon-like peptide-1 based multi-agonists. Mol Cell Endocrinol 2015; 418: 42-54
    CrossrefPubMedSuche in Google Scholar
  • 28 Barrington P, Chien JY, Tibaldi F. et al. LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects. Diabetes Obes Metab 2011; 13: 434-438
    CrossrefPubMedSuche in Google Scholar
  • 29 Bush MA, Matthews JE, Boever EHD. et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects. Diabetes Obes Metab 2009; 11: 498-505
    CrossrefPubMedSuche in Google Scholar
  • 30 Marso SP, Bain SC, Consoli A. et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375: 1834-1844
    CrossrefPubMedSuche in Google Scholar
  • 31 Xia L, Shen T, Dong W. et al. Comparative efficacy and safety of 8 GLP-1RAs in patients with type 2 diabetes: A network meta-analysis. Diabetes Res Clin Pract 2021; 177: 108904
    CrossrefPubMedSuche in Google Scholar
  • 32 Andersen A, Lund A, Knop FK. et al. Glucagon-like peptide 1 in health and disease. Nat Rev Endocrinol 2018; 14: 390-403
    CrossrefPubMedSuche in Google Scholar
  • 33 Deacon CF, Nauck MA, Toft-Nielsen M. et al. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995; 44: 1126-1131
    CrossrefPubMedSuche in Google Scholar
  • 34 Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol 2019; 10
    CrossrefPubMedSuche in Google Scholar
  • 35 Mahapatra MK, Karuppasamy M, Sahoo BM. Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes. Rev Endocr Metab Disord 2022; 23: 521-539
    CrossrefPubMedSuche in Google Scholar
  • 36 Lau J, Bloch P, Schäffer L. et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem 2015; 58: 7370-7380
    CrossrefPubMedSuche in Google Scholar
  • 37 Niman S, Hardy J, Goldfaden RF. et al. A review on the efficacy and safety of oral semaglutide. Drugs RD 2021; 21: 133-148
    CrossrefPubMedSuche in Google Scholar
  • 38 Olds J, Milner P. Positive reinforcement produced by electrical stimulation of septal area and other regions of rat brain. J Comp Physiol Psychol 1954; 47: 419-427
    CrossrefPubMedSuche in Google Scholar
  • 39 Drevets WC, Gautier C, Price JC. et al. Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biol Psychiatry 2001; 49: 81-96
    CrossrefPubMedSuche in Google Scholar
  • 40 Marty VN, Farokhnia M, Munier JJ. et al. Long-acting glucagon-like peptide-1 receptor agonists suppress voluntary alcohol intake in male wistar rats. Front Neurosci 2020; 14: 599646
    CrossrefPubMedSuche in Google Scholar
  • 41 Quddos F, Hubshman Z, Tegge A. et al. Semaglutide and tirzepatide reduce alcohol consumption in individuals with obesity. Sci Rep 2023; 13: 20998
    CrossrefPubMedSuche in Google Scholar
  • 42 Fink-Jensen A, Wörtwein G, Klausen MK. et al. Effect of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide on alcohol consumption in alcohol-preferring male vervet monkeys. Psychopharmacology (Berl) 2024;
    CrossrefPubMedSuche in Google Scholar
  • 43 Granhall C, Donsmark M, Blicher TM. et al. Safety and pharmacokinetics of single and multiple ascending doses of the novel oral human GLP-1 analogue, oral semaglutide, in healthy subjects and subjects with type 2 diabetes. Clin Pharmacokinet 2019; 58
    CrossrefPubMedSuche in Google Scholar
  • 44 Andreadis P, Karagiannis T, Malandris K. et al. Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis. Diabetes Obes Metab 2018; 20: 2255-2263
    CrossrefPubMedSuche in Google Scholar
  • 45 Fadini GP, Sarangdhar M, Avogaro A. Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA Adverse Event Reporting System. BMJ Open Diabetes Res Care 2018; 6: e000475
    CrossrefPubMedSuche in Google Scholar
  • 46 Rehfeld JF, Knop FK, Asmar A. et al. Cholecystokinin secretion is suppressed by glucagon-like peptide-1: Clue to the mechanism of the adverse gallbladder events of GLP-1-derived drugs. Scand J Gastroenterol 2018; 53: 1429-1432
    CrossrefPubMedSuche in Google Scholar
  • 47 He L, Wang J, Ping F. et al. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: A systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med 2022; 182: 513-519
    CrossrefPubMedSuche in Google Scholar
  • 48 Mahapatra MK, Karuppasamy M, Sahoo BM. Therapeutic potential of semaglutide, a newer GLP-1 receptor agonist, in abating obesity, non-alcoholic steatohepatitis and neurodegenerative diseases: A narrative review. Pharm Res 2022; 39: 1233-1248
    CrossrefPubMedSuche in Google Scholar